Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bafna PharmaceuticalsNSE:BAFNAPH +2.00%60 Graham Number is ₹65.49 as of Mar. 2026, which is 100% below its 10-year median of 1.68. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 60/100 and a GF Value™ of ₹91.06 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 604 Drug Manufacturers companies, Bafna Pharmaceuticals ranks worse than 82.95% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
The historical rank and industry rank for Bafna Pharmaceuticals's Graham Number or its related term are showing as below:
NSE:BAFNAPH'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.45 Med: 1.68 Max: 3.77
Current: 3.5
During the past 13 years, the highest Price to Graham Number ratio of Bafna Pharmaceuticals was 3.77. The lowest was 1.45. And the median was 1.68.
NSE:BAFNAPH's Price-to-Graham-Number is ranked worse than 82.95% of 604
companies
in the Drug Manufacturers industry
Industry Median: 1.54
vs NSE:BAFNAPH: 3.50
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
Bafna Pharmaceuticals (NSE:BAFNAPH) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Bafna Pharmaceuticals's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Mar. 2026 )
=
225.88
/
65.49
=
3.45
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Bafna Pharmaceuticals Graham Number Related Terms
Bafna Pharmaceuticals Graham Number Historical Data
* Premium members only.
The historical data trend for Bafna Pharmaceuticals's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:BAFNAPH vs ZTS, UTHR: Graham Number Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bafna Pharmaceuticals Price-to-Graham-Number vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where Bafna Pharmaceuticals's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bafna Pharmaceuticals (NSE:BAFNAPH) has a Graham Number of ₹65.49 as of Mar. 2026. The Graham Number values a company based on its per-share earnings and book value. View historical data on Bafna Pharmaceuticals and its competitors. This is 3798% above median its historical median of 1.68. Over the past decade, Bafna Pharmaceuticals' Graham Number has ranged from 1.45 to 3.77. According to the industry distribution chart, Bafna Pharmaceuticals ranks #501 out of 604 companies in the Drug Manufacturers industry, placing it in the top 82.9%.
Is Bafna Pharmaceuticals' Graham Number too high?
Bafna Pharmaceuticals' current Graham Number of ₹65.49 is 3798% above median its 10-year median of 1.68. Over the past 10 years, this metric has ranged from a low of 1.45 to a high of 3.77. Based on the distribution chart, Bafna Pharmaceuticals ranks #501 out of 604 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bafna Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' Graham Number compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bafna Pharmaceuticals ranks #501 out of 604 companies for Graham Number. This places Bafna Pharmaceuticals in the lower half of its industry. The industry median Graham Number is 1.54. Historically, Bafna Pharmaceuticals' own Graham Number has ranged from 1.45 to 3.77 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Drug Manufacturers company?
The median Graham Number among Drug Manufacturers companies is 1.54, based on 604 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on Bafna Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Graham Number is 1.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bafna Pharmaceuticals's current Graham Number is ₹65.49, which is 3798% above median its own 10-year median of 1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹91.06, compared to a current price of ₹225.88 — trading 148.1% above its estimated fair value. The current Graham Number is ₹65.49, which is 3798% above median its 10-year median of 1.68. Bafna Pharmaceuticals' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current Graham Number is ₹65.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?
Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹225.88 is trading 148.1% above its estimated GF Value™ of ₹91.06.
GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:BAFNAPH:
Graham Number: ₹65.49 (3798% above median its 10-year median of 1.68)
GF Value™: ₹91.06 vs. price of ₹225.88 (148.1% above fair value)
No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
60GF Score
Get the complete analysis for NSE:BAFNAPH
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BAFNAPH has been successfully added to your 
